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Abstract
Interest in the patient’s views of his or her illness and treatment has increased dramatically. However, our ability to
appropriately measure such issues lags far behind the level of interest and need. Too often such measurement is
considered to be a simple and trivial activity that merely requires the application of common sense. However,
good quality measurement of patient-reported outcomes is a complex activity requiring considerable expertise and
experience. This review considers the most important issues related to such measurement in the context of
chronic disease and details how instruments should be developed, validated and adapted for use in additional
languages. While there is often consensus on how best to undertake these activities, there is generally little
evidence to support such accord. The present article questions these orthodox views and suggests alternative
approaches that have been shown to be effective.
Opinion
Questionnaires are ubiquitous throughout life these
days. Medicine is no different, with the patient rightly
seen as a client whose views are crucial to gaining a
clear understanding of anything from the quality of
service provision to treatment effectiveness. Patients
are increasingly regarded as one of the key stakeholder
groups in medicine that, alongside regulators, payers
and clinicians, can influence access to and reimburse-
ment for pharmaceutical products. Much of the infor-
mation on patient views is collected via questionnaires.
Many, if not most, of these are hastily prepared by
clinical or other professionals wishing to answer speci-
fic questions that they consider to be important.
Unfortunately, the development and application of
such questionnaires is often regarded as a matter of
‘common sense’ requiring little scientific consideration.
However, in this area of research, common sense is
commonly nonsense! In this article, I argue that many
of the questionnaires patients are asked to complete in
clinical practice and trials are of poor quality and col-
lect information that is of scant relevance to the
patient. In this respect, they are ultimately of limited
value.
Questionnaires used to elicit information from
patients are now commonly referred to as patient-
reported outcome measures (PROMs). A PROM is far
more than a mechanism for gathering opinion. They are
designed to measure a specific concept (that is, a con-
struct) in a standardised way. Thus, they provide a
means of quantifying qualitative information. In reality,
there is a great deal of science involved in producing
good-quality PROMs. Indeed, the PROM development
process requires careful consideration of several key
issues as set out in Figure 1.
When selecting a PROM, it is crucial that evidence is
available to show that each of these key issues has been
considered and addressed during instrument develop-
ment and testing. Where measures are required for use
in different languages or cultures, there are additional
considerations: Have appropriate methods been
employed to translate the questionnaire? Have new lan-
guage versions been tested to ensure that they are both
suitable for local patients and have adequate psycho-
metric and scaling properties?
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Patient-reported outcome (PRO) is an umbrella term
that covers a range of different types of outcome (see
Table 1). Symptoms and functioning are clearly defined
as impairments and disability in the International Classi-
fication of Impairment, Disability and Handicap [1]. Dis-
ability is now referred to as activity [2]. PROMs should
not be confused with clinical rating scales, where a clini-
cian completes a form to rate disease severity or treat-
ment effects. The common link between PROMs is that
they collect information directly from the patient with-
out interpretation by clinicians or others [3-5]. However,
this does not imply that all PROMs measure issues that
are of concern or importance to the patient.
Measures of symptoms, activity limitations, health sta-
tus, health-related quality of life (HRQL) and quality of life
(QoL) completed by patients are all examples of PROMs
[3,6]. More recently, PROMs have also been used in clini-
cal trials to address issues of patient satisfaction, compli-
ance with treatment and treatment preferences. Each of
these outcomes represents a distinct measurement con-
struct and these should not be confused. Indeed, the term
‘PRO’ was coined in about 2000 specifically to avoid the
misuse of, and the confusion surrounding, the term ‘qual-
ity of life’. It had been (and occasionally still is) common
practice for instrument developers to refer to any PROM
as a measure of QoL, even where it was clearly designed
to address a different outcome construct [7].
Figure 1 Key considerations for patient-reported outcome questionnaire development. The major factors that should be considered when
selecting a patient-reported outcome measurement (PROM) for use in clinical studies are shown. These emphasise the importance of ensuring
that the PROM addresses the required outcome, that it has been carefully developed and that all versions developed (including language
adaptations) are of good quality.
McKenna BMC Medicine 2011, 9:86
http://www.biomedcentral.com/1741-7015/9/86
Page 2 of 12To summarise, PROMs that assess symptoms (that is,
impairment) or functional limitations (such as disability
or activity limitations) address issues that are of primary
interest to the clinician, as th e s ea r em o s ti n d i c a t i v eo f
disease severity. HRQL measures are made up of scales
that assess symptoms and activity limitations. In con-
trast, QoL scales determine outcomes that are of pri-
mary concern to the patient. Severe impairment or
functional limitations may well also be of concern to the
patient, but only where these affect QoL. QoL scales
should provide a holistic assessment of the impact of
disease and its treatment on the patient.
Unfortunately, when describing PROMs, few authors
state the model used to generate its content. Instead, it
is common practice to describe a range of different con-
structs that should be measured. However, there is lim-
ited agreement about the specific constructs that should
be assessed [8]. Of the measurement models described
in the literature, the most widely applied QoL model is
concerned with the extent to which disease and its
treatment prevent an individual from meeting his or her
needs [9-13]. This approach argues that individuals are
driven or motivated by their needs and that the fulfil-
ment of these provides satisfaction and a good QoL [9].
Consequently, QoL is good when most needs are ful-
filled and poor when few needs are satisfied. Function-
ing is important only insofar as it permits need
fulfilment. For example, employment has the objective
of earning a salary, but it also leads to the fulfilment of
a number of basic human needs (see Figure 2). Satisfac-
tion of these needs leads to a good QoL.
Measures of satisfaction differ from HRQL and QoL,
as they address the process of treatment rather than its
outcome. These measures are concerned with factors
such as acceptability of the drug and the quality of care.
Some PROMs, such as the EQ-5D [14] and the Health
Utilities Index [15], can be used to generate preference
or utility assessments. Patients’ responses to these ques-
tionnaires can be converted to estimate the value of that
person’sl i f eo nas c a l er a n g i n gf r o md e a t h( s c o r e d0 )
through to perfect health (rated 1). As these PROMs
consist of items enquiring about impairments and func-
tional limitations, they are measures of HRQL. Such
PROMs are referred to in this article as measures of uti-
lity, as they are widely used for this purpose in clinical
trials. Recently, utility valuations have been derived from
responses to disease-specific QoL instruments, providing
more accurate measurement of this construct [16-20].
This article concentrates primarily on PROMs that
assess more than a single symptom (such as pain or
Table 1 Types of patient-reported outcome measures
a
Type of PRO Constructs assessed Examples of coverage/domains
Symptoms Impairment · Pain
· Fatigue
· Anxiety
· Depression
· Incontinence
Functioning Disability/activity · Bathing
· Dressing
· Walking
· Ability to work
· Activities of daily living (such as personal care)
Health status
(HRQL)
Combination of impairment, disability and, occasionally,
some QoL
· Symptoms and functions as above
Quality of life QoL · Needs-based QoL
Utility
b Combination of impairment, disability or QoL · Symptoms and functions as above
· Activities of daily living (such as personal care)
· Needs-based QoL
aPRO, patient-reported outcome; HRQL, health-related quality of life; QoL, quality of life;
bresponses to the questionnaire are used to generate a perceived utility
score.
Figure 2 Employment-related needs. The relationships between
function, objective and needs satisfaction are shown. Here
employment is a function undertaken to obtain income. However,
undertaking the function leads to the satisfaction of a range of
needs (some of which are listed). Quality of life (QoL) is the result of
satisfaction of the needs rather than earning an income per se.
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that do not measure satisfaction or utility and that are
used in clinical trials or for monitoring patients in clini-
cal practise.
Generic versus disease-specific PROs
Regardless of the construct assessed, a PROM may be
generic or disease-specific. As its name implies, a gen-
eric instrument is intended to be used in any disease
population. Some of the more widely known PROMs
are generic. Examples include the Sickness Impact Pro-
file (SIP) [21], the Nottingham Health Profile (NHP)
[22], the Short Form 36 (SF-36) [23] and the EQ-5D
[14]. Such instruments usually assess several domains
and provide a profile of scores.
Traditionally, generic instruments were used to pro-
vide comparisons between diseases or to compare data
with population normative values. However, the results
of differential item functioning analyses show that such
comparisons are scientifically flawed, as questionnaire
items work in different ways with different patient
groups [24-27]. This means that as generic measures
cannot allow valid comparisons to be made between the
impacts of different diseases or between healthy and dis-
eased populations, they no longer have a clear role in
measuring health outcomes.
A second major problem with generic instruments is
that they are not designed to capture areas of concern
to specific patient populations. This raises two issues.
First, they are likely to include items that are irrelevant
for certain patient groups. For example, questions that
address physical functioning or bodily pain will only be
relevant if they are a feature of the disease under study.
Asking patients to answer questions that are irrelevant
is likely to alienate respondents and increase the poten-
tial for missing or inaccurate responses. Second, they
are likely to miss issues that are a specific feature of the
disease under study. As a result, generic scales lack the
responsiveness needed to measure change associated
with effective treatment.
As a result of the acknowledgement of the problems
with generic measures, they are no longer developed.
They have partly been replaced by item-banking
approaches whereby a subset of relevant items for a spe-
cific condition is selected to assess patients. The most
widely used generic measures are relatively dated. The
SIP and NHP were developed in the early 1970s. The
five items included in the EQ-5D were taken from exist-
ing generic measures and so are of the same vintage.
Most of the items in the SF-36 were adapted from
instruments that had been used for 20 to 40 years pre-
vious to 1992 [23]. The way in which patients concep-
tualise their problems and the language with which they
express themselves can change within a generation.
Moreover, certain issues may become less important
with time. For example, lack of mobility may be com-
pensated for by advances in technology. Furthermore,
the generic health status instruments have not benefited
from improvements in test construction methodology
and scaling techniques. Consequently, the reliability and
responsiveness of the generic measures fall far short of
what is required for instruments included in clinical
trials.
Disease-specific questionnaires are developed to
address those aspects of outcome that are important for
a particular patient population. In the case of needs-
based QoL measures, this is achieved by generating the
items by means of qualitative interviews with relevant
patients and by thoroughly testing the validity of the
item set with new populations of patients. More com-
plex analyses are also employed to ensure that all items
actually assess the construct being measured [13,28].
Thus, for a well-developed measure, patients will only
be asked questions that are relevant, meaningful and
acceptable to them. Addressing the relevant areas of
concern for the group under study maximizes respon-
dent acceptability and minimises missing data. Conse-
quently, disease-specific instruments possess greater
potential for showing differences between competing
therapies. A criticism that is often made of the use of
disease-specific scales is the lack of comparability across
diseases. This is a particular issue for reimbursement
authorities, who are required to assess the comparative
benefits of treatment reimbursement across disease
areas. However, as noted above, the use of generic scales
does not provide a valid basis for comparison across dis-
eases. Recent advances in scaling theory are being
applied to address this issue. It is now feasible to use
disease-specific measures to make across-disease com-
parisons, providing the instruments are based on the
same model of the construct measured.
Use of PROMs in medicine
PROMs have been used in a variety of ways in clinical
practice and research. At the level of the individual
patient, they can be used to assess disease severity and
response to interventions. Here the measures can be
used to help in decision making at the physician level.
PROs are also widely used in clinical trials to determine
whether an intervention is effective (for example, when
evaluating treatments for pain) and also whether
patients feel the benefit of treatments. Evidence pro-
vided by PROMs can thus aid decisions made by regula-
tory bodies regarding the utility of new products. Figure
3 shows schematically the different types of PROMs
used in medicine. The diagram reflects the fact that
most PROMs currently used assess HRQL rather than
QoL or patient satisfaction. The assessment of QoL is
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research reports and publications.
The widespread use of HRQL measures gives some
cause for concern. First, the term itself is misleading
and unhelpful insofar as it implies that QoL is being
measured. Bradley [29] argued that ‘clinicians may be
misled into thinking that findings based on a [HRQL]
instrument indicate that treatments do not damage QoL
when all the data reveal is that treatments do not
damage perceived health’ (page 7). Indeed, the focus on
HRQL provides a framework for assessing interventions
predominantly from a clinical rather than a patient per-
spective. Second, HRQL scales do not necessarily
address issues of primary concern to the patient. The
focus of HRQL on the patient’s ability to fulfil roles
deemed ‘normal’ takes no account of the fact that
patients with chronic disease adapt to their condition,
often by replacing activities that they can no longer per-
form with others that are equally satisfying. Patients
may give up functions that become problematic and
take up other leisure activities to maintain their QoL.
For example, while muscular degenerative disease
patients may experience ambulatory problems, they can
still remain independent and thus maintain a reasonable
level of QoL through the use of a walking frame or
wheelchair. HRQL measures are unable to cope with
such adaptations, making it difficult for severely ill or
disabled patients to show improvement even following
effective interventions.
QoL is the primary outcome of relevance and impor-
tance to patients. When dealing with chronic diseases,
the aim is frequently stated to be to improve the QoL of
patients. This is particularly true where therapies cannot
promise a cure or an extension to life. QoL is not
intended to be an aid to diagnosis or a guide to the
most appropriate intervention for a specific patient.
However, its careful assessment should be able to deter-
mine which alternative interventions patients as a group
would prefer within the context of a clinical trial.
Despite this crucial role, there are several other require-
ments of clinical trials. For example, a product must be
shown to improve objective health status and to be
cost-effective. There are several chronic conditions for
which steroid treatment improves QoL but does not
necessarily improve the patient’s health status in the
long term.
The needs-based model of QoL resulted from analys-
ing the transcripts from patient interviews conducted
during the development of the Quality of Life in
Depression Scale [9]. Figure 2 illustrates how the func-
tion of employment fits into the needs model. The
objective purpose of employment is to earn money.
However, being employed can lead to the satisfaction of
a wide range of needs. Depressed patients who were
unable to be employed reported problems with structur-
ing their days, with identity and status and with reduced
social interaction. Such needs can also be met in differ-
ent ways, for example, by doing voluntary work or by
joining sporting or interest clubs [30]. Research has
shown that unemployed people who stay active in these
ways are able to maintain their health [31].
The needs-based approach to QoL assessment has a
number of advantages for measurement of the impact of
disease and its treatment. Rather than asking directly
about a function, it is possible to enquire about the
needs that could be satisfied by that function. For exam-
ple, questions about sexual performance are frequently
left unanswered in questionnaires because of their irrele-
vance or unacceptability. The needs approach allows
questions to be asked about needs related to sexual
functioning that can also be satisfied in other ways, such
as love, intimacy, touching and sharing with another
person. The needs-based approach also copes well with
patient adaptation. A chronically ill person can maintain
a reasonable level of QoL by remaining independent
through the use of aids and/or assistance. Patients who
have activity limitations can still be shown to have a
good QoL, as the concern here is the degree to which
Figure 3 Types of PROMs currently used in medical research.
The range of different types of patient-reported outcomes (PROs) is
shown. The most commonly used PROMs assess symptoms and/or
functional limitations. These are commonly referred to as health-
related quality of life (HRQL) measures. The commonly used
measures which generate utility values also ask about symptoms
and/or functional limitations. Patient satisfaction is generally
concerned with issues such as the process of treatment and
relationships with clinical staff. QoL measures address need-
fulfilment rather than symptoms and/or functional limitations.
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achieved.
Measures developed using the needs-based approach
are disease-specific (or could be more appropriately
described as disease-relevant). This allows them to focus
on the specific needs interfered with by the disease and
hence makes them highly relevant and acceptable to the
patient. As specific needs may be affected by different
illnesses, it is possible to develop valid methods of mak-
ing comparisons between the impacts of different
diseases.
A further advantage of the needs-based measures is
that they assess the single construct of need satisfaction,
allowing the construction of unidimensional scales or
indices of QoL. A major problem of HRQL measures is
that they collect information on a range of different
types of outcomes. Consequently, they provide a profile
of scores (see, for example, the NHP [22], the SIP [21]
and the SF-36 [23]). It is not possible to compare scores
on the different sections of the profile, and it is certainly
unacceptable simply to add together responses to the
different sections to give a single score, although this is
common practice in outcome measurement.
Selecting and using PROMs for clinical trials and
studies
The inclusion of poorly designed or inadequately tar-
geted instruments in a clinical trial or study can have
serious consequences. Furthermore, ethical questions
are raised by asking patients to complete measures that
are incapable of demonstrating treatment effects. It is
strongly recommended that expert help is sought in
selecting an appropriate PROM. Too often the choice is
based on issues that are helpful rather than being of
scientific importance. PROMs may be selected because
they are commonly used, are used by a competitor or
are available in a wide range of languages. While such
factors can be helpful, they are minor compared with
what the questionnaire actually measures and how well
it does this.
When selecting a PROM, it is first necessary to deter-
mine the constructs that have to be assessed to meet
the objectives of the study. Having done this, the next
s t a g ei st of i n dP R O st h a tm e a s u r et h e s ec o n s t r u c t s
well. It is not advisable to rely on, or to be limited to,
the PROMs listed in databases such as OLGA [32] or
the Patient-Reported Outcome and Quality of Life
Instruments Database (PROQOLID) [33]. Such sources
of information are often selective and/or omit important
measures. Furthermore, they rely on test authors to pro-
vide information on the quality of the measures listed
without providing any commentary on the acceptability
of testing methods used or the appropriateness of the
conclusions drawn. A thorough search of the medical
literature should be made to find available measures and
evaluate their suitability for use in the trial. This will
often generate a host of potential PROMs that will vary
considerably in terms of the care with which they were
developed and their psychometric quality.
Selecting the most appropriate questionnaire requires
consideration of several keyq u a l i t ys t a n d a r d s .T h e s e
cover the development processes, instrument scaling,
psychometric properties and cultural translation and
adaptation processes (Figure 4) [6]. These standards are
described in detail in the Appendix.
It is increasingly common for trials to include PROMs.
In some cases, they have been accepted as primary end
points by the health authorities. However, these PROMs
actually measure clinical end points (such as pain) that
cannot be determined objectively. Indeed, the US Food
and Drug Administration (FDA) prefers these types of
PROs to be employed, as they appear to be uncomforta-
ble with more subjective outcomes [34,35]. This con-
trasts with the European Medicines Agency (EMA),
which welcomes QoL outcomes that describe the added
benefits of new products [36]. Both the EMA and the
FDA emphasise that outcome measures selected for a
study should be well targeted to the specific patient
population, which fundamentally rules out the use of
generic PROMs. It is noticeable that both bodies now
c o n s i d e rt h em o s tw i d e l yu s e dP R O M ,t h eS F - 3 6 ,t ob e
unsuitable for making claims about the value of treat-
ments. Indeed, this measure has such poor psychometric
properties that it has never proved to be a valuable
instrument for showing differences between active treat-
ments (see, for example, [37] and [38]). Indeed, it has
been shown that sample sizes of up to 20,000 per study
arm would be required for SF-36 domains to be able to
show such differences [39].
Where the instrument is used as a clinical end point
in a trial and/or is intended to be used to support a pro-
duct label claim or to provide information for inclusion
in the Summary of Product Characteristics, it is neces-
sary to agree in advance with the appropriate authorities
that data collected with the measure will be acceptable
to them. This generally involves providing a detailed
briefing book. The briefing book must include informa-
tion on how each item was generated and the reasons
for rejecting items. Evidence is required for the whole
testing procedure and the development and validation of
all language versions of the measure to be used in the
trial. Problems will occur with older measures, where
such information is unlikely to be available and/or the
development methodology was inadequate. Where a
new measure is being developed for a specific trial, it is
prudent to keep the authority informed at each stage of
instrument development. The EMA now has a biomar-
ker qualification system in operation that allows PRO
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been achieved, the EMA will accept all data collected in
a trial that uses the measure. The FDA has also issued a
draft guidance document covering PRO instrument qua-
lification [41].
Sufficient time should be allowed to ensure that the
required language versions of a measure have been
developed and validated (see below). Very often poor
quality translations are produced, relying on simple for-
ward-backward translation techniques rather than using
an approach that involves relevant patients. Adapting
measures appropriately is a time-consuming procedure
that needs to be built into trial planning.
Once an instrument has been selected, it is crucial
that its value and the reasons for its use are clear to
everyone involved in the trial. If this is not done, data
collection with the measure will be of debatable value.
Staff involved in the trial at each centre will require
training on the application of the measure and how to
deal with problems that might arise.
Development and validation of PRO measures
Where a search fails to identify a high-quality PROM for
a trial, it will require that a new questionnaire be devel-
oped. However, planning for such an event is important,
as the development process can be time-consuming,
particularly if several language versions of the measure
are required. I would argue strongly that the content for
such a measure should be generated by means of one-
to-one patient interviews, as the content should be rele-
vant and acceptable to future patients.
There are four key stages in instrument development:
(1) identification of the measurement model, (2) genera-
tion of questionnaire content, (3) content refinement
and item reduction and (4) scaling and psychometric
evaluation. These stages are summarised in Table 2
[42-44].
Adapting PRO measures
If the required language versions are known from the
outset, instrument development should be conducted in
parallel in these countries [45,46]. However, this infor-
mation is rarely available, and it is more common for
subsequent language adaptations to be required. Again,
it is necessary to allow sufficient time for such adapta-
tions to be produced, as the process can be time-
consuming.
Translation procedures
Translating PROMs is a complex task that cannot be
undertaken lightly without the risk of producing poor-
quality adaptations. It is commonly stated that forward-
Figure 4 Brief checklist for assessing the quality of PRO instruments. The specific requirements of a good-quality PROM are shown. These
qualities should be clearly reported in peer-reviewed publications. In many cases (including that of the most commonly employed PROMs), this
information is not available. New instrument development methodologies, in particular the establishment of the scaling properties of a measure
(item response theory), are essential to ensuring the quality of PROMs.
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methodology [47]. However, there is no evidence to sup-
port this view; it is merely a statement of belief. When
such translation work was first handed to translators,
test developers felt the need to assess the quality of the
new version by some sort of ‘scientific’ method. This led
to the introduction of forward-backward translation.
However, such a methodology raises the hackles of
translators, and not only because it casts inappropriate
doubts on their abilities. If the translation is good, then
the back-translation may well look nothing like the
source questionnaire. Consequently, little information of
value is obtained by conducting the backward transla-
tion, while misleading impressions can result. Instead,
quality should be built into every stage of the translation
procedure rather than checking it a posteriori.
Rather than relying on forward-backward translation, a
dual-panel methodology has been developed and is now
commonly employed (see Table 3). A recent study has
shown that the ‘dual panel’ methodology produces
translations that are more acceptable to patients in the
new country than the use of forward-backward transla-
tion [48].
It is important to remember that this is only the start
of the adaptation process. The new translation should
then be tested by means of face-to-face interviews with
several relevant patients to ensure that the adapted ver-
sion has face and content validity (known as ‘cognitive
debriefing’). Finally, the psychometric properties of the
adapted questionnaire must be established with new
patient samples. This requires a test-retest survey to be
conducted for each new language version produced.
Such retesting is rarely undertaken but is necessary to
show that the new language version works in the same
way as the original, evidence that is required by the
FDA [35].
Conclusions
The development, administration, analysis and adapta-
tion of PROMs must be carried out by highly skilled
specialists. Too often nonspecialists are given the tasks
of determining which outcomes should be included in
clinical studies and trials and how these should be mea-
sured. Unfortunately, this largely explains why few such
studies provide useful data. Such a situation represents a
waste of resources and the opportunity to show the ben-
efits of expensive new products. A more professional
approach to assessing PROs is needed. Of particular
concern is the paucity of QoL studies undertaken, given
that high-quality measures specific to several diseases
are available [49].
Selecting the best PROMs for a trial should be given
the same consideration as choosing clinical outcome
measures. Too often PROMs are selected at too late a
stage to allow required language adaptations to be
Table 2 Development and validation of QoL measures
There are four key stages in instrument development:
▶ Identification of measurement model: QoL scales should be based on a
stated model or theory of QoL.
▶ Generation of questionnaire content: Content of all QoL scales should
be derived from interviews with relevant patients. Both the concerns
and the wording used in the items should be generated during these
interviews. Thirty to thirty-five interviews are usually sufficient to
generate items. Qualitative analysis of the transcripts allows the
construction of a QoL outcome model for the disease.
▶ Content refinement and item reduction: Content validity is assessed by
comparing the issues covered by the items to the outcome model.
Retained items should be clearly expressed, address only one issue,
avoid duplication, be potentially capable of change and apply to all
respondents. The draft measure should then be tested with a new set
of patients to check comprehension, ability to answer the measure and
ensure item relevance.
▶ Scaling and psychometric evaluation: Formal testing of dimensionality,
reproducibility and construct validity should be achieved by means of a
test-retest survey. In most European countries and North America, the
survey can be conducted by post. A sample of 100 or more is
preferable. It is strongly recommended that this stage should employ
Item Response Theory techniques [42,43].
aQoL, quality of life.
Table 3 Recommendations for the production of high-
quality adaptations
The dual panel method is recommended for producing high-quality
translations. The following recommendations are made:
Recruit ‘translators’ who currently live in the target country and
whose command of English is good.
The meeting should be held in the country for which the
measure is required.
Five to seven people enable fruitful discussion.
It is preferable to exclude professional translators.
An instrument developer should attend this meeting to explain the
intent of the items and their specific meanings in the context of
the questionnaire.
Inform the group of the model underlying the questionnaire, how
it was developed, its design and its content and target audience.
Inform the group of the translation requirements (in particular
accessibility and acceptability of wording).
The group should work as a team with a co-ordinator whose task
is to check that none of the parameters are neglected (in
particular, structural and metric aspects that could be overlooked).
Allow adequate time for the meeting to explore all issues fully.
Once the translated version of the instrument is agreed, have it
assessed by a lay panel, again working as a group:
The coordinator involved in the first panel should work with
this panel also to ensure that the original meaning of the
items and the questionnaire structure are maintained.
The results of this meeting should be used to make final
decisions about the wording of the questionnaire.
The whole procedure should be reported in detail, in
particular explaining translation choices and changes made
following lay panel testing. This not only provides information
on the process undertaken but also constitutes a thorough
final review.
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selected. It is common for very expensive clinical trials
to waste the opportunity to assess QoL or other PROs
appropriately because of lack of planning or unwilling-
ness to pay for the necessary development work. In rea-
lity, the cost of such work is minimal in comparison to
the overall cost of the trial.
The development of PROMs is far from a common-
sense procedure. Success is dependent on both expertise
and experience. Table 4 lists some of the issues covered
in this article. Many if not most of the points listed are
counter to the commonsense view on outcome mea-
surement and instrument development.
Given the expressed desire of organizations such as
the FDA and the EMA to be made aware of the benefits
of treatment from the consumer’s perspective and the
need to convince payers of the added benefit of new
treatments, it is to be hoped that more attention will be
paid in future to the assessment of the effects of new
interventions from the patient’s perspective.
The science of PROMs is developing quickly. For too
long, outdated generic HRQL measures such as the SF-
36, NHP and EQ-5D have been relied on in clinical
studies. It is now well understood that such measures are
inadequate for showing change over time or the different
impacts of alternative interventions. Greater emphasis is
now placed on measurement models, disease-specific
measurement and the application of Item Response The-
ory rather than Classical Test Theory. Well-developed
measures are now generally of better quality and are
more sensitive than many clinical outcome measures.
The development and use of PROMs have suffered
from a lack of theory and poor basic development work
for far too long. We have been willing to continue using
the same poor generic PROMs because we are familiar
with them, despite their age, lack of quality and inability
to do the job for which they are intended. Given the
cost of clinical trials and the importance of evaluating
health services from the perspective of the patient, it is
essential that the quality of PROMs improves. It is also
time to reject the view that the only valid PROs are
symptom scores and limited functional assessments
mimicking clinical outcomes. It is important for PRO
practitioners to argue strongly on behalf of the patient
that we should also measure carefully those outcomes
that really matter to them.
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Appendix
Development and validation of patient-reported outcome
measures
There are four key stages in instrument development:
(1) identification of the measurement model, (2) genera-
tion of questionnaire content, (3) content refinement
and item reduction and (4) scaling and psychometric
evaluation.
Identification of the measurement model
The requirement for a measurement model appears to
be common sense: How else is it possible to decide
which items to include in the measure? However, it is
astounding how infrequently test developers report the
measurement model that guided the development of
their measurement instrument. Measures of symptoms
or functioning may well be based on the World Health
Organisation’s International Classification of Function-
ing, Disability and Health classification of impairments
and activity limitations, respectively [1,2]. A measure of
quality of life (QoL) is likely to be based on the needs-
Table 4 A new common sense for patient-reported
outcome assessment
a
Do not rely on instrument databases for PRO identification and
selection.
HRQL consists of symptoms, functions and limited aspects of the
impact of these.
HRQL is very different from QoL.
The needs-based model of QoL is the most widely employed in
medical research.
True QoL has rarely been measured in clinical studies and trials.
The content of QoL measures must be derived from relevant patients.
PROMs must be simple to administer, complete and score.
Simple two-point response formats are preferable to multiple response
formats [43].
All PROMs used in clinical trials should be disease-specific.
Generic PROMs do not allow the impact of different diseases on
patients to be compared.
Population norms for PROMs are invalid.
Think twice before selecting generic measures such as the EQ-5D to
determine utility estimates, as they have limited psychometric quality.
QoL is a unidimensional construct.
Data collected using PROMs must be shown to be unidimensional.
Scores on subscales can rarely be added together to give a total score.
High reliability (reproducibility) is crucial to the accuracy of PROMs.
Forward-backward translation is a flawed methodology, creating
unnecessary work.
Think carefully before using PROMs developed in the Western world in
Asia and Africa.
Evidence is required of the scalability, reproducibility and construct
validity of all language versions of PROMs used in a clinical trial.
aPRO, patient-reported outcome; PROM, patient-reported outcome measure;
HRQL, health-related quality of life; QoL, quality of life.
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Page 9 of 12based model of QoL [9]. The model employed should be
reported in the instrument development publication to
allow readers the opportunity to consider whether the
measure employed is reasonable and practical.
Generation of questionnaire content
The development of patient-reported outcome (PRO)
instruments is a highly skilled activity best undertaken
by specialists in measurement and psychometrics. It is
particularly important that the content of these instru-
ments is generated by researchers experienced in quali-
tative interviewing techniques. Content for all PRO
measures (PROMs) should be derived from interviews
with relevant patients (for QoL scales) or experts and/or
patients (for measures of health-related quality of life).
Thus, if a measure of QoL specific to endometriosis is
required, the content will be derived from qualitative
interviews conducted with women experiencing the pro-
blem. Such interviews are not intended to explore issues
identified in the literature or by clinical experts. Both
the relevant concerns and the wording used in the inter-
view questions must be generated during these inter-
views. This is the most crucial stage of instrument
development and must be carried out by skilled specia-
lists. If good-quality questionnaire items are not identi-
fied, the resulting instrument will be poor.
The interviews, which may last several hours, should
be audio-recorded and transcriptions produced. It is
generally found that 30 to 35 interviews are sufficient to
generate items for a scale. Additional interviews tend
not to identify new issues of importance. Interviewees
will generally raise specificf u n c t i o n st h a ta r ep r o b l e -
matic for them. The skill of the interviewer is to probe
such responses carefully to understand how the patient’s
life is impaired by such restricted functioning. The
needs-based model of QoL grew out of such probing in
the development of the Quality of Life in Depression
Scale [9]. Depressed patients who were unable to work
reported problems with structuring their days, with
identity and status and with reduced social interaction
(see Figure 1).
Qualitative analysis of the transcripts allows the con-
struction of a PRO model for the disease. This model
will identify the issues and/or needs that are relevant for
assessment of patients with the disease studied. The
analysis will also identify potential items for inclusion in
the measure. Where possible, it is preferable to keep the
wording used by interviewees for the items, although
minor changes may be necessary. Items are then best
expressed as statements made by patients, such as ‘I’ve
lost interest in food’ or ‘I feel dependent on other peo-
ple’. Stating the items in this form leads to a response
format of ‘yes’ or ‘no’ or ‘true’ or ‘not true’.T h i si sa
natural way of responding to items that should enquire
into issues that are clear-cut. The application of modern
psychometric models (such as Rasch analysis) indicates
that increasing the number of possible responses for an
item does not increase the sensitivity of the scale.
Instead, the final set of items should each represent a
different amount of the construct measured in the same
way that the marks on a ruler denote different lengths.
Content refinement and item reduction
Patient interviews will identify a large set of potential
items. Content validity is assessed by comparing the
issues covered by the items to the outcome model and
other sources of information about the impact of the
disease. The first stage of item reduction involves ensur-
ing that items are clearly expressed. For example, they
should address only one issue, avoid duplication, be
potentially capable of change with effective treatment
(for example, avoiding statements such as ‘Iw o r r yt h a t
my illness will become worse’) and apply to all respon-
dents. Items that are not relevant are poor, as they lead
to ambiguous responses.
Scaling and psychometric evaluation
The next stage is to test the draft questionnaire with a
new set of relevant patients by means of cognitive
debriefing interviews. These items will explore intervie-
wee’s ability to understand and complete the measure
and ensure that items are considered relevant. In this
way, the face validity of the measure will be established.
Changes in wording can still be made at this stage, and
i t e m sc a nb er e m o v e do ra d d e da sar e s u l to ft h e
interviews.
Formal testing of the questionnaire for dimensionality,
reproducibility and construct validity is then undertaken
by means of a test-retest survey. In most European and
North American countries, the survey can be conducted
by post. While test-retest reliability (reproducibility) can
be assessed with a sample of around 50, the need to
determine the dimensionality of the scale means that a
sample of 100 or more is preferable.
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